SBUX:NASDAQStarbucks Corporation Analysis
Data as of 2026-06-07 - not real-time
$95.29
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Starbucks is trading just above its near‑term support of $93.64 with the 20‑day SMA ($102.20) comfortably above the 50‑day SMA ($99.59) and the 200‑day SMA ($91.36), signalling a bullish long‑term trend. However, the 14‑day RSI sits at 33, indicating the stock is oversold, while the MACD line remains below its signal, a bearish short‑term cue. Volume is on the rise and the beta of 0.73 suggests lower market‑wide volatility, yet the 30‑day price volatility exceeds 30%, reflecting heightened price swings. The valuation metrics are stark: a trailing P/E of 73 and a DCF‑derived fair value of roughly $31 place the current price of $95.29 in the overvalued zone.
Fundamentally, revenue grew 8.8% YoY and operating margins are modest at 8.4%, but free cash flow is negative and debt sits at $24.4 B with a negative book value per share, eroding balance‑sheet strength. The dividend yield of 2.6% looks attractive but the payout ratio of 188% is unsustainable. Recent news of AI inventory tool glitches and corporate layoffs underscores operational challenges and cost‑cutting efforts, while the CEO’s participation in a consumer‑retail conference and a lean drive‑thru expansion signal continued strategic focus. Analyst consensus remains a “Buy” with a median price target of $110, implying modest upside despite the current overvaluation.
Fundamentally, revenue grew 8.8% YoY and operating margins are modest at 8.4%, but free cash flow is negative and debt sits at $24.4 B with a negative book value per share, eroding balance‑sheet strength. The dividend yield of 2.6% looks attractive but the payout ratio of 188% is unsustainable. Recent news of AI inventory tool glitches and corporate layoffs underscores operational challenges and cost‑cutting efforts, while the CEO’s participation in a consumer‑retail conference and a lean drive‑thru expansion signal continued strategic focus. Analyst consensus remains a “Buy” with a median price target of $110, implying modest upside despite the current overvaluation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above technical support
- Bearish MACD signal despite bullish SMA crossover
- Elevated 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth of ~9% with ongoing drive‑thru expansion
- Cost‑reduction initiatives including layoffs and office closures
- Analyst price targets averaging $106‑$110
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong global brand and franchise network
- Potential for international market penetration
- Long‑term dividend yield despite current sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth8.80%
Profit Margin3.89%
P/E Ratio72.7
ROA7.38%
P/B Ratio-12.8
Op. Cash Flow$4.3B
Free Cash Flow$-1304087552
Technical Analysis
TrendBullish
RSI33.4
Support$93.64
Resistance$108.88
MA 20$102.20
MA 50$99.59
MA 200$91.36
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02
Valuation
Fair Value$31.24
Target Price$106.25
Upside/Downside11.50%
GradeOvervalued
TypeBlend
Dividend Yield2.60%
Risk Assessment
Beta0.73
Volatility30.02%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.